Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
January 2013, Vol 4, No 1
January 2013, Vol 4, No 1
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
By
Caroline Helwick
Health Economics
January 2013, Vol 4, No 1
Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.
Read Article
Applying Whole-Genome Analysis to Treatment Decisions in Daily Practice
By
Caroline Helwick
Personalized Medicine
January 2013, Vol 4, No 1
Vienna, Austria—Several studies presented at the 2012 European Society for Medical Oncology Congress offered a look into what many believe will lead to the application of genome-based biomarker information into clinical use based on the concept of personalized medicine, although not all of the results were unconditionally encouraging.
Read Article
Abiraterone versus Placebo before Chemotherapy for Patients with Metastatic Prostate Cancer
In the Literature
January 2013, Vol 4, No 1
A recent study compared the benefit of abiraterone acetate (Zytiga) with prednisone versus placebo plus prednisone for patients with mCRPC before chemotherapy (Ryan CJ, et al.
N Engl J Med
. 2013;368:138-148).
Read Article
Low Socioeconomic Status Impedes Access to Early-Phase Clinical Trial for Patients with Cancer
In the Literature
January 2013, Vol 4, No 1
Ensuring access to clinical trials to all patients is important not only to ensure equal access to care but also to make sure that clinical trial results can be generalized to all patients in the real-world setting. For the first time, a team of British researchers has recently investigated this question, revealing important implications for healthcare stakeholders (Noor AM, et al.
J Clin Oncol
. 2012;31:224-230).
Read Article
Marker Helps Identify Most Aggressive Metastasized Breast Tumors
By
Rosemary Frei, MSc
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Boston, MA—Researchers believe they are closing in on a better way to identify breast cancers that are particularly dangerous and therefore require more aggressive therapy.
Read Article
Rivaroxaban More Cost-Effective than Warfarin in the Prevention of Recurrent VTE
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
For the prevention of recurrent venous thromboembolism (VTE), rivaroxaban (Xarelto) appears to be more cost-effective than warfarin (Coumadin), an independent analysis undertaken by the University of Pittsburgh School of Medicine showed.
Read Article
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—Support for the oral immunomodulatory agent pomalidomide for the treatment of multiple myeloma took a giant step forward when new data from the phase 3 MM-003 trial showed a survival advantage in patients with advanced disease.
Read Article
Oprozomib Shows Promise in Hematologic Malignancies
By
Lynne Lederman, PhD, Medical Writer
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—Promising preliminary results for oprozomib (ONX 0912), an orally available structural analogue of carfilzomib (Kyprolis), were presented at the 2012 American Society of Hematology meeting.
Read Article
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—MLN9708, an investigational oral proteasome inhibitor, produced impressive results in a phase 1/2 clinical trial of treatment-naïve patients with multiple myeloma that was featured in a press briefing at the 2012 American Society of Hematology (ASH) meeting.
Read Article
Rasburicase Cost-Effective for Tumor Lysis Syndrome
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
A study using real-world data for patients with tumor lysis syndrome (TLS) showed that treatment with rasburicase (Elitek) was associated with significantly greater reductions in uric acid, length of hospital stay, and total hospitalization costs per patient compared with allopurinol (Zyloprim).
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma